A carregar...
ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome
T cell immunotherapies are often thwarted by the limited presentation of tumor-specific antigens abetted by the downregulation of human leukocyte antigen (HLA). We showed that drugs inhibiting ALK and RET produced dose-related, increases in cell surface HLA in tumor cells bearing these mutated kinas...
Na minha lista:
| Publicado no: | Cancer Immunol Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6891198/ https://ncbi.nlm.nih.gov/pubmed/31540894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0056 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|